1Hulley S,Grady D,Bush T,et al.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women[J].JAMA,1998,280(7):605-13.
2Hulley S,Furberg C,Barrett-Connor E,et al.Noncardiovascular disease outcomes during 6.8 years of hormone therapy.Heart and Estrogen/progestinReplacement Study follow-up (HERS II)[J].J Am Med Assoc,2002,288(1):58-66.
3Manson JE,Hsia J,Johnson KC,et al.Estrogen plus progestin and the risk of coronary heart disease[J].N Engl J Med,2003,349(6):523-34.
4Xing D,Nozell S,Chen YF,et al.Estrogen and mechanisms of vascularprotection[J].Arterioscler Thromb Vasc Biol,2009,29(3):289-95.
5Meyer MR,Haas E,Barton M.Gender differences of cardiovascular disease:new perspectives for estrogen receptor signaling[J].Hypertens ion,2006,47(6):1019-26.
6Prossnitz ER,Maggiolini M.Mechanisms of estrogen signaling and geneexpression via GPR30[J].Mol Cell Endocrinol,2009,308(1-2):32-8.
7Prossnitz ER,Arterburn JB,Smith HO,et al.Estrogen signaling through the transmembrane G protein-coupled receptor GPR30[J].Annu Rev Physiol,2008,70:165-90.
8Deschamps AM,Murphy E.Activation of a novel estrogen receptor,GPER,is cardioprotective in male and female rats[J].Am J Physiol Heart Circ Physiol,2009,297(5):H1806-13.
9Kim ES,Menon V.Status of women in cardiovascular clinical trials[J].Arterioscler Thromb Vasc Biol.2009,29(3):279-83.
10Anderson RD,Pepine CJ.Gender differences in the treatment for acutemyocardial infarction:bias or biology[J]? Circulation,2007,115(7):823-6.
